NEW YORK (TheStreet) -- Endocyte (ECYT) - Get Report shares are down 6.4% to $6.54 on Tuesday after Brean Capital downgraded the stock to "hold" from "buy".

The downgraded outlook stems from the firm's belief that the biotech company's investigational target cancer therapeutic treatment, Vintafolide, will only produce marginal returns for the company.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

ECYT

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.